- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00006001
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced Colorectal Cancer
Studieoversigt
Detaljeret beskrivelse
OBJECTIVES:
I. Determine the objective response rate and disease stabilization rates of patients with previously treated metastatic or locally recurrent colorectal cancer treated with SU5416.
II. Determine the median and overall survival and time to progression in this patient population receiving this treatment.
III. Determine the toxicity of SU5416 in these patients.
OUTLINE: This is a multicenter study.
Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
Patients are followed every 2 weeks for 4 weeks.
PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study within 12-18 months.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois at Chicago
-
Chicago, Illinois, Forenede Stater, 60640
- Louis A. Weiss Memorial Hospital
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Cancer Research Center
-
Decatur, Illinois, Forenede Stater, 62526
- Cancer Care Specialists of Central Illinois, S.C.
-
Evanston, Illinois, Forenede Stater, 60201
- Evanston Northwestern Health Care
-
Park Ridge, Illinois, Forenede Stater, 60068
- Division of Hematology/Oncology
-
Peoria, Illinois, Forenede Stater, 61602
- Oncology/Hematology Associates of Central Illinois, P.C.
-
Springfield, Illinois, Forenede Stater, 62701
- Central Illinois Hematology Oncology Center
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46885-5099
- Fort Wayne Medical Oncology and Hematology, Inc.
-
South Bend, Indiana, Forenede Stater, 46617
- Michiana Hematology/Oncology P.C.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
- Histologically confirmed metastatic or locally recurrent adenocarcinoma of the colon or rectum
- Progressive disease as defined by new or progressive radiologic lesions
- Measurable disease at least 1 dimension as at least 20 mm with conventional techniques or at least 10 mm with spiral CT scan
- Lesions seen on colonoscopic examination or barium studies, bone metastases, CNS lesions, CEA levels and ascites are not considered measurable
- Lesion accessible for biopsy which is not within prior radiation port
- Known history of CNS metastasis allowed if patients have had treatment, are neurologically stable, and do not require oral or intravenous steroids or anticonvulsants, provided brain scan (CT or MRI) shows absence of active or residual disease
- If neurologic signs or symptoms suggestive of CNS metastasis, negative brain scan required
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: WHO 0-2
- Life expectancy: At least 12 weeks
- WBC at least 3,000/mm3
- Platelet count at least 75,000/mm3
- Bilirubin no greater than 1.5 mg/dL
- Transaminases no greater than 2.5 times upper limit of normal
- Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min
- No uncompensated coronary artery disease
- No history of myocardial infarction or severe/unstable angina within past 6 months
- No severe peripheral vascular disease associated with diabetes mellitus
- No deep venous or arterial thrombosis within past 3 months
- No pulmonary embolism within past 3 months
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other significant uncontrolled underlying medical or psychiatric illness
- No serious active infections
- No concurrent second malignancy except for nonmelanoma skin cancer or carcinoma in situ of the cervix unless completed therapy and considered to be at less than 30% risk of relapse
- No history of severe allergic or anaphylactic reactions to paclitaxel or docetaxel
PRIOR CONCURRENT THERAPY:
- No more than 2 prior chemotherapy regimens for metastatic disease
- At least 4 weeks since prior chemotherapy
- No concurrent chemotherapy
- No other concurrent investigational antineoplastic drugs
- No prior radiotherapy to only site of measurable disease
- At least 4 weeks since prior radiotherapy and recovered
- No concurrent radiotherapy
- At least 30 days since other prior investigational drugs
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm I
Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks.
Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer
- Neoplasmer efter sted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Tyktarmssygdomme
- Tarmsygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Kolorektale neoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Proteinkinasehæmmere
- Semaxinib
Andre undersøgelses-id-numre
- NCI-2012-02345
- UCCRC-NCI-52
- NCI-52
- CDR0000068009 (Registry Identifier: PDQ (Physician Data Query))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kolorektal cancer
-
University of ArkansasAktiv, ikke rekrutterendeColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAktiv, ikke rekrutterendeMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater
Kliniske forsøg med semaxanib
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)AfsluttetUspecificeret fast tumor hos voksne, protokolspecifikForenede Stater
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)AfsluttetTumorer i hjernen og centralnervesystemetForenede Stater
-
National Cancer Institute (NCI)AfsluttetSarkom | Gastrointestinal stromal tumorForenede Stater
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AfsluttetHoved- og halskræft | Ikke-melanomatøs hudkræft | Karcinom af ukendt primærForenede Stater
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)AfsluttetMyelom og plasmacelle-neoplasmaForenede Stater
-
PfizerAfsluttet
-
City of Hope Medical CenterNational Cancer Institute (NCI)AfsluttetNyrekræftForenede Stater
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Afsluttet
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Afsluttet
-
National Cancer Institute (NCI)AfsluttetStadie IV nyrecellekræft | Tilbagevendende nyrecellekræftForenede Stater